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The mechanism of human sex determination has attracted much public and scientific interest in light of ongoing discussions regarding gender and sex in both these spheres. The increasing societal focus on transgender rights to sexual and gender self-expression has raised fundamental questions regarding appropriate medical management of newborns with androgynous genitalia. Understanding the function of the SRY gene is pivotal to these discussions. Located on the Y chromosome, activation of SRY determines the sex of a fetus by initiating Sertoli-cell differentiation and a cascade of events leading to development of the testes. Abnormalities within the gene can cause gonadal dysgenesis and a female somatic phenotype (XY sex reversal, also known as Swyer syndrome).
Racca et al. [1] studied an XY daughter whose mutation was also found in the SRY sequence of her father, uncle, and two brothers. While she exhibited certain symptoms of this mutation (in the form of somatic XY sex reversal, primary amenorrhea, and gonadoblastoma), her uncle and father did not and maintained regular fertility. This inheritance pattern indicated that this particular SRY mutation is compatible with either male or female development, presumably depending on other genetic variables.
Racca et al. undertook a two-pronged investigation. First, they explored the consequences of the mutation by focusing on the protein region in which SRY abnormalities primarily occur: the high-mobility-group (HMG) box. By conducting biochemical and biophysical experiments, investigators determined that the mutation is inherently destabilizing, and yet it shares similar specific DNA-binding and -bending properties with wild-type SRY.
Second, they evaluated the cell biological functions of the mutant SRY (compared to wild type) in platforms of cultured mammalian cells (rat and human cell lines). Investigators used a rat cell derived from the developing XY gonadal-ridge cells as a model for SRY-directed male sex initiation; these cells were isolated by Patricia K. Donahoe prior to the onset of endogenous SRY actions, therefore providing an appropriate cellular milieu for such studies. A control line was generated from the same embryonic stage of rat development that neither responded to transfected SRY nor possessed pre-Sertoli markers, thus establishing a ''non-Sertoli-related lineage.'' Coordinate use of human cell lines indicated that the results were not restricted to rodents.
Investigators noted elevated polyubiquitination of the mutant SRY, a modification that was associated with accelerated proteasomal degradation. This phenomenon led to a reduced intracellular SRY concentration. Lower amounts of cellular SRY triggered a concurrent reduction in the total number of human SRY binding to the testis-specific enhancer of Sox9 (TES), leading in turn to a reduction in Sox9 transcriptional activation, the key step in male sex determination. Such activation could be rescued by treating the cells with a chemical proteasome inhibitor. This treatment restored SRY levels, TES occupancy, and Sox9 expression to wild-type values.
These findings are significant for genetic studies of sexual development and its anomalies, as they reveal, possibly for the first time, a proteasome-based mechanism that obstructs normal gonadogenesis. Indeed, the results illuminate the architecture of SRY and may have implications for how a narrow ''window of opportunity'' for SRY-directed testis determination is regulated within the bipotential gonadal ridge. By unraveling the biological determinants of sex, the scientific community has gained a clearer grasp on the nuances of sexual identityknowledge that could be used for responsible policymaking and social advances.
